Skip to main content

Table 1 Characteristics and assessment of the PAP cohort

From: A mini-whole lung lavage to treat autoimmune pulmonary alveolar proteinosis (PAP)

 

Study group [n = 7]

Control group [n = 6]

 

Age, years [mean ± SD]

42.7 ± 16

53.3 ± 9.4

 

Ratio male/female

4/3

3/3

 

Smoking status [n (%)]

   

 Current

1 (14.28%)

1 (16.66%)

 

 Previous

2 (28.57%)

3 (50.00%)

 

 Never

4 (57.14%)

2 (33.33%)

 

Symptoms at diagnosis [n (%)]

   

 Dyspnoea

5 (71.42%)

5 (83.33%)

 

 Cough

5 (71.42%)

4 (66.66%)

 

 Fever

2 (28.57%)

 

 Fatigue

2 (28.57%)

 

Biomarkers [mean ± SD]

   

 Cyfra 21.1 (ng/mL)

11.85 ± 8.7

16 ± 11.26

(nv: 0.0–3.3)

 CEA (ng/mL)

13.71 ± 13.46

18 ± 20.07

(nv: 0.0–5.0)

 NSE (ng/mL)

24 ± 11.60

21.33 ± 14.19

(nv: 0.0–15.0)

 GMAbs (μg/mL)

108.44 ± 80.33

216.20 ± 263.63

(nv < 3)

Infection at diagnosis [n (%)]

4 (57.14%)

3 (50.00%)

 

Time to diagnosis, months [mean (range)]

7 (1–23)

4 (0–16)

 

1° lung flooding time, minutes [mean ± SD]

34 ± 8

50 ± 8

 

2° lung flooding time, minutes [mean ± SD]

29 ± 2

48 ± 9

 
  1. Cyfra 21.1 cytokeratin fragment 21.1; CEA carcinoembryonic antigen; NSE neuron-specific enolase; GMAbs autoantibodies anti GM-CSF, SD standard deviation; nv normal value